Current cough and sputum assessed by the cough and sputum assessment-questionnaire (CASA-Q) is associated with quality of life impairment in cystic fibrosis.


Journal

BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563

Informations de publication

Date de publication:
21 Nov 2023
Historique:
received: 12 06 2023
accepted: 09 10 2023
medline: 23 11 2023
pubmed: 22 11 2023
entrez: 22 11 2023
Statut: epublish

Résumé

Cough and sputum are major symptoms in cystic fibrosis (CF) that contribute to the impairment of quality of life. This prospective single centre cross-sectional pilot study aimed to evaluate the results of a self-administered questionnaire assessing cough and sputum symptoms (2 domains), and their impact (2 domains) on daily activities in the previous week, named the Cough and Sputum Assessment Questionnaire (CASA-Q) in CF adult patients at stable state, and to analyse associations with clinical, functional, microbiological, radiological data, and two quality of life scales: the Cystic Fibrosis Questionnaire Revised (CFQ-R) and the Saint George Respiratory Questionnaire (SGRQ). Forty-eight patients were included in this analysis (69% men; median age of 27.8 ± 8.1 years; median body mass index of 21.8 + 3.3 kg/m²; mean FEV CASA-Q allows the assessment of cough and sputum in CF adult patients and is associated with quality of life impairment. This simple easy-to-use tool could be used in routine clinical practice and in clinical studies to assess cough and sputum in CF patients. The study was registered on ClinicalTrials.gov (NCT02924818, first posted on 5th October 2016).

Sections du résumé

BACKGROUND BACKGROUND
Cough and sputum are major symptoms in cystic fibrosis (CF) that contribute to the impairment of quality of life.
METHODS METHODS
This prospective single centre cross-sectional pilot study aimed to evaluate the results of a self-administered questionnaire assessing cough and sputum symptoms (2 domains), and their impact (2 domains) on daily activities in the previous week, named the Cough and Sputum Assessment Questionnaire (CASA-Q) in CF adult patients at stable state, and to analyse associations with clinical, functional, microbiological, radiological data, and two quality of life scales: the Cystic Fibrosis Questionnaire Revised (CFQ-R) and the Saint George Respiratory Questionnaire (SGRQ).
RESULTS RESULTS
Forty-eight patients were included in this analysis (69% men; median age of 27.8 ± 8.1 years; median body mass index of 21.8 + 3.3 kg/m²; mean FEV
CONCLUSIONS CONCLUSIONS
CASA-Q allows the assessment of cough and sputum in CF adult patients and is associated with quality of life impairment. This simple easy-to-use tool could be used in routine clinical practice and in clinical studies to assess cough and sputum in CF patients.
TRIAL REGISTRATION BACKGROUND
The study was registered on ClinicalTrials.gov (NCT02924818, first posted on 5th October 2016).

Identifiants

pubmed: 37990322
doi: 10.1186/s12890-023-02701-3
pii: 10.1186/s12890-023-02701-3
pmc: PMC10664648
doi:

Banques de données

ClinicalTrials.gov
['NCT02924818']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

457

Informations de copyright

© 2023. The Author(s).

Références

Proc Am Thorac Soc. 2007 Aug 1;4(4):378-86
pubmed: 17652505
Respir Investig. 2019 May;57(3):252-259
pubmed: 30738923
J Cyst Fibros. 2003 Mar;2(1):29-34
pubmed: 15463843
Arch Bronconeumol. 2007 Apr;43(4):205-11
pubmed: 17397584
Nat Rev Genet. 2015 Jan;16(1):45-56
pubmed: 25404111
Lancet. 2009 May 30;373(9678):1891-904
pubmed: 19403164
Qual Life Res. 2003 Feb;12(1):77-85
pubmed: 12625520
Radiology. 2008 Mar;246(3):697-722
pubmed: 18195376
Health Qual Life Outcomes. 2022 Oct 6;20(1):141
pubmed: 36203159
Chest. 2005 Oct;128(4):2347-54
pubmed: 16236893
Clin Exp Allergy. 2019 Jun;49(6):781-788
pubmed: 30710420
Qual Life Res. 2012 Sep;21(7):1279-90
pubmed: 22240933
Pediatr Clin North Am. 2016 Aug;63(4):567-84
pubmed: 27469176
Open Respir Med J. 2016 Dec 30;10:105-108
pubmed: 28217196
Respir Med. 2010 Apr;104(4):534-41
pubmed: 19917525
Physiotherapy. 2020 Jun;107:243-251
pubmed: 32026826
Respir Med. 2008 Nov;102(11):1545-55
pubmed: 18662868
J Pediatr. 1990 May;116(5):714-9
pubmed: 2109790
Int J Chron Obstruct Pulmon Dis. 2016 Sep 13;11:2091-2097
pubmed: 27695305
Glob J Health Sci. 2013 Sep 16;5(6):131-41
pubmed: 24171881
J Cyst Fibros. 2009 Jul;8(4):245-52
pubmed: 19481983
Respirology. 2018 Jan;23(1):46-54
pubmed: 28718995
J Psychosom Res. 2011 Feb;70(2):161-7
pubmed: 21262419
Acta Paediatr Scand Suppl. 1989;363:52-6; discussion 56-7
pubmed: 2701925
Int J Chron Obstruct Pulmon Dis. 2020 Jan 29;15:201-212
pubmed: 32099345
J Cyst Fibros. 2017 May;16(3):425-432
pubmed: 27986494
Radiology. 2002 Dec;225(3):663-72
pubmed: 12461244

Auteurs

Lucie Charon (L)

Service des Maladies Respiratoires et Allergiques, CHU de Reims, Reims, France.

Claire Launois (C)

Service des Maladies Respiratoires et Allergiques, CHU de Reims, Reims, France.

Jeanne-Marie Perotin (JM)

Service des Maladies Respiratoires et Allergiques, Université de Reims Champagne-Ardenne, INSERM, CHU de Reims, P3Cell, U 1250, Reims, France.

Bruno Ravoninjatovo (B)

Service des Maladies Respiratoires et Allergiques, CHU de Reims, Reims, France.

Pauline Mulette (P)

Service des Maladies Respiratoires et Allergiques, CHU de Reims, Reims, France.

Julien Ancel (J)

Service des Maladies Respiratoires et Allergiques, Université de Reims Champagne-Ardenne, INSERM, CHU de Reims, P3Cell, U 1250, Reims, France.

Thomas Guillard (T)

Laboratoire de Bactériologie-Virologie-Hygiène hospitalière- Parasitologie-Mycologie, Université de Reims Champagne-Ardenne, INSERM, CHU de Reims, P3Cell, Reims, U 1250, France.

Anaëlle Muggeo (A)

Laboratoire de Bactériologie-Virologie-Hygiène hospitalière- Parasitologie-Mycologie, Université de Reims Champagne-Ardenne, INSERM, CHU de Reims, P3Cell, Reims, U 1250, France.

Valérian Dormoy (V)

INSERM UMRS 1250, Université de Reims Champagne-Ardenne, Reims, France.

Muriel Griffon (M)

Service des Maladies Respiratoires et Allergiques, CHU de Reims, Reims, France.

Sophie Carré (S)

Service des Maladies Respiratoires et Allergiques, CHU de Reims, Reims, France.

François Lebargy (F)

Service des Maladies Respiratoires et Allergiques, Université de Reims Champagne-Ardenne, EA7509 IRMAIC, CHU de Reims, Reims, France.

Gaëtan Deslée (G)

Service des Maladies Respiratoires et Allergiques, Université de Reims Champagne-Ardenne, INSERM, CHU de Reims, P3Cell, U 1250, Reims, France.

Sandra Dury (S)

Service des Maladies Respiratoires et Allergiques, CHU de Reims, Reims, France. sdury@chu-reims.fr.
EA7509 IRMAIC, Université de Reims Champagne-Ardenne, Reims, France. sdury@chu-reims.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH